Post-earnings recap
Reported
Tue, Oct 23, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Edwards Lifesciences reported a slight beat on EPS, which indicates some positive momentum in profitability. However, the stock fell by 0.68% in reaction, likely due to the lack of revenue data and forward guidance. Investors may be cautious given the absence of specific future expectations from management.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.07 | N/A | +0.03% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed confidence in the company's product pipeline and market position. They emphasized the need for continued innovation to meet customer needs.
Management highlighted ongoing demand for their heart valve products.
They noted the importance of innovation in driving future growth.
There was a focus on maintaining operational efficiency.